Show summary Hide summary
- What the new trials found about higher semaglutide doses
- Trial design and participant profiles
- How much more weight did people lose?
- Side effects and safety signals to watch
- What experts say: effectiveness versus long-term concerns
- Who funded the research and why that matters
- How GLP-1 drugs work and the options available
- Practical guidance for patients and clinicians
Two large clinical trials suggest that higher weekly doses of semaglutide produce greater weight loss than the current standard dose, offering a potential new tool for obesity care — but also raising questions about long-term safety and access.
What the new trials found about higher semaglutide doses
Published in The Lancet Diabetes & Endocrinology, the two randomized studies tested a 7.2 mg weekly semaglutide regimen against the 2.4 mg dose and placebo.
Eggs every day for months: simple check reveals shocking blood test result
Popular childhood food ingredient may raise adult anxiety: study
- Non-diabetic trial: 1,407 adults with obesity lost an average of 19% body weight on 7.2 mg, versus 16% on 2.4 mg and about 4% on placebo.
- Diabetes trial: 512 adults with obesity and type 2 diabetes lost an average of 13% on 7.2 mg, versus 10% on 2.4 mg and roughly 4% on placebo.
The higher dose also produced larger improvements in waist circumference, blood pressure, cholesterol, and blood sugar in the trials.
Trial design and participant profiles
Researchers enrolled people across many countries and sites to gather diverse data.
Non-diabetes study
- 1,407 participants at 95 sites in 11 countries.
- Average age: 47. Mean BMI: ~40. About 73% women.
- Follow-up ran from January 2023 through November 2024.
Diabetes study
- 512 participants at 68 sites, studied between January and May 2023.
- Average age: 56. Mean BMI: 38. Mean HbA1c slightly above 8.
- About 52% of participants were female.
How much more weight did people lose?
The 7.2 mg dose produced modest but meaningful additional losses compared with the approved 2.4 mg dose.
- Non-diabetic group: 19% average weight loss on 7.2 mg; one in two reached at least 20% loss.
- Diabetic group: 13% average weight loss on 7.2 mg.
- Placebo arms in both studies showed roughly 4% average weight loss.
Side effects and safety signals to watch
Participants on higher doses reported mostly gastrointestinal complaints. Researchers called them manageable.
- Nausea, vomiting, and diarrhea were more common but usually temporary.
- Investigators also noted an increase in sensory symptoms labeled dyseasthesia — skin sensitivity, burning or pain.
- Dyseasthesia appeared more frequent at the higher dose (22.9% vs 6%), and nearly 19% of those affected had not recovered by the study end.
Scientists emphasize that long-term risks and the durability of benefits require further study.
What experts say: effectiveness versus long-term concerns
Outside specialists welcomed the stronger weight-loss signal, while urging caution about chronic use.
- Surgeons and obesity specialists call GLP-1s the most effective medicines available for weight loss today.
- Some experts note bariatric surgery remains the most durable option for eligible patients.
- Clinicians warn that stopping medication often leads to weight regain, so many patients need prolonged treatment.
Off-label dosing and insurance coverage are practical hurdles. The FDA-approved weekly dose for semaglutide in weight management is 2.4 mg. Using 7.2 mg would be outside those regulatory boundaries.
Who funded the research and why that matters
Both trials were funded by Novo Nordisk, the maker of semaglutide brands such as Ozempic and Wegovy.
Industry funding does not invalidate results, but independent follow-up studies can help confirm safety and generalizability.
How GLP-1 drugs work and the options available
GLP-1 receptor agonists mimic a hormone that reduces appetite and helps control blood sugar.
- Semaglutide-based drugs include Wegovy (approved for weight management), Ozempic and Rybelsus (approved for type 2 diabetes).
- Tirzepatide products, such as Mounjaro and Zepbound, act on related pathways and are available by injection.
- Formulations can be injections or oral tablets, depending on the drug.
Clinical studies have linked these medicines to benefits beyond weight loss, including potential heart, brain, and cancer risk improvements.
Practical guidance for patients and clinicians
Experts stress medication should be part of a broader care plan.
- Weight-loss drugs work best combined with dietary counseling, exercise plans, and behavioral support.
- Regular follow-up allows clinicians to adjust therapy and monitor side effects.
- Patients should discuss possible off-label dosing and out-of-pocket costs with their providers and insurers.
Doctors warn that medications are tools to support long-term lifestyle change, not standalone cures.
